Pursuant to section 20 of the Medicines Act 1981, the Minister of Health hereby consents to the distribution in New Zealand of the new medicines which were referred to the Minister of Health under the provisions of section 24(5) of the Act and are set out in the Schedule hereto:
Schedule
Product: Sandostatin LAR
Active Ingredient: Octreotide acetate 11.2mg
Dosage Form: Powder for injection with diluent
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Sandoz GmbH, Tyrol, Austria
Product: Sandostatin LAR
Active Ingredient: Octreotide acetate 22.4mg
Dosage Form: Powder for injection with diluent
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Sandoz GmbH, Tyrol, Austria
Product: Sandostatin LAR
Active Ingredient: Octreotide acetate 33.6mg
Dosage Form: Powder for injection with diluent
New Zealand Sponsor: Novartis New Zealand Limited
Manufacturer: Sandoz GmbH, Tyrol, Austria
Dated this 2nd day of August 2013.
DR STEWART JESSAMINE, Acting Chief Medical Officer, Clinical Leadership, Protection and Regulation Business Unit, Ministry of Health (pursuant to delegation given by the Minister of Health on 6 July 2001).